JPMorgan Downgrades Pfizer (PFE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
BMO Capital Reiterates Market Perform on Pfizer (PFE) Following Investor Meetings
December 13, 2018 7:34 AM ESTBMO Capital analyst, Alex Arfaei, reiterated a Market Perform rating and $46.00 price target on Pfizer (NYSE: PFE) following recent investor meetings with management. Overall, management's commentary was in line with Arfaei's bullish views on most assets.
Management was very bullish about the... More
